Increased Revenue from HEPZATO
Revenue from HEPZATO sales increased to $19.3 million in Q3 2025 compared to $10 million in the same period in 2024.
Positive CHOPIN Trial Results
CHOPIN trial showed significant improvements in the primary endpoint with 1-year PFS at 54.7% in the combination group versus 15.8% in the perfusion group.
Expansion of Treatment Sites
25 REMS-certified treatment sites with plans to expand to 40 by the end of 2026.
High Gross Margins
The company recognized gross margins of 87% in Q3 2025 compared to 85% in the same period last year.
Strong Cash Position
Ended the quarter with approximately $89 million in cash and investments and positive operating cash flow of $4.8 million.